CBDA (Cannabidiolic Acid): What It Is and What Is Known
CBDA is the raw acid form of CBD. Here is what it is, how it differs from CBD, what animal and cell studies suggest, and why human evidence is missing.
Content last updated . This page has not been medically reviewed.
Overview and classification
CBDA (cannabidiolic acid) is the acid form of CBD (cannabidiol). It is the main cannabinoid in fiber and seed-oil hemp plants, and its possible health effects were overlooked for years because scientists focused on CBD. [1] CBDA is one of four acidic precursors, alongside THCA, CBGA and CBCA, of the better-known neutral cannabinoids. [2]CBDA and THCA are constitutional isomers: the same atoms arranged differently. [1] Unlike THCA, CBDA's neutral form (CBD) is not the intoxicating compound. See CBD and THCA.
Evidence labels used on this page: preclinical (cells/animals only), insufficient evidence, marketing claim. Approved medicines are kept separate: the FDA-approved CBD medicine Epidiolex contains purified CBD, not CBDA, so its results do not apply to CBDA. [3]
Where it comes from and how it relates to CBD
Cannabis makes cannabinoids in acid form, and the acids lose a carbon-dioxide group (decarboxylation) with heating, processing and storage. [4] Cannabinoid acids generally break down with light, air and heat, and a laboratory study of commercial hemp seed oils examined how quickly CBDA breaks down under different storage conditions. [5] The plant builds CBDA from the shared precursor CBGA using its own enzyme, CBDA synthase. [6]Raw (unheated) plant material therefore contains the acid, while products that have been heated or aged can contain more of the neutral form. This page does not describe how to convert one into the other.
What research shows
| Question | Label | What the sources say |
|---|---|---|
| Nausea and vomiting | preclinical (cells/animals only) | A review of laboratory and in vivo evidence concluded CBD reduces nausea and vomiting, with CBDA and a methylated version (CBDA-ME) being more potent, and called for clinical trials. [7] CBDA has been reported effective for nausea and anxiety in rodents. [8] |
| Pain | preclinical (cells/animals only) | In a mouse model of Rett syndrome and in male mice, a low dose of CBDA reduced thermal pain sensitivity. [8] |
| Absorption | preclinical (cells/animals only) | In cell and mouse experiments, CBDA had significantly better bioavailability than CBD. [9] This is not a human result. |
| Any health condition in people | insufficient evidence | A 2026 review lists chemical instability, low bioavailability and a dearth of controlled human trials as barriers. [2] |
Proper evidence not found for benefit or safety in people. We checked PubMed abstracts for CBDA reviews, animal studies and bioavailability work; none reported a human clinical outcome. A pharmacokinetics review adds that data on acidic forms such as CBGA and CBCA is thinner than for CBD, and that clinical research is the biggest gap. [10]
Marketing claims
Some products are promoted as "raw CBD" or "CBDA-rich" with claims of stronger effects than CBD. Those are marketing claims. The better-absorption finding above comes from mice and cells, and no human study read for this page shows that it means better results in people. A cultivar or product name is not proof of how much CBDA it holds; check verified batch data. See CBD vs CBDA on a label and product quality and certificates of analysis.Regulatory category (United States, read 2026-10-22)
The FDA quotes the 2018 Farm Bill definition of hemp as the plant and all derivatives, extracts, cannabinoids, isomers and acids, with a delta-9 THC concentration of not more than 0.3 percent on a dry weight basis. [3] The FDA also says it has not approved a marketing application for cannabis for any disease or condition. [3] The Congressional Research Service reports that this hemp definition is being amended to use total THC, with portions delayed to December 11, 2026. [11] A rule specific to CBDA was not verified. Other countries and US states were not verified. Laws change, and this is not legal advice. See cannabis and CBD laws by country.Safety and special groups
Safety of CBDA in people has not been established by the sources read. If a product also contains CBD or THC, their risks apply; see CBD and medication interactions. People who are pregnant, breastfeeding, have liver disease, or take regular medicines should check with a clinician first. Keep products away from children; in the US, call Poison Help at 1-800-222-1222 or 911 in an emergency.Frequently asked questions
What is CBDA?
CBDA is the acid form of CBD and the main cannabinoid in fiber and seed-oil hemp. [1]
Is CBDA the same as CBD?
No. They are related, and the plant makes CBDA first. Heat, light, air and time change cannabinoid acids into their neutral forms. [4] [5]
Does CBDA help with nausea or anxiety?
Only animal and laboratory evidence exists, in rodents. [8] [7] Proper evidence not found in people.
Is CBDA better absorbed than CBD?
In one study using cells and mice, yes. [9] Whether this applies to people is unknown.
Is CBDA legal?
It depends on where you are and what the product is. See the US summary above and the laws page. This is not legal advice.
References
- Formato et al. (-)-Cannabidiolic Acid, a Still Overlooked Bioactive Compound: An Introductory Review and Preliminary Research. Molecules. 2020. PubMed abstract read 2026-10-22.
- Singh et al. Therapeutic potential of acidic cannabinoids: an update. Journal of Cannabis Research. 2026. PubMed abstract read 2026-10-22.
- US Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD): Questions and Answers. Read 2026-10-22.
- Nadal et al. Tetrahydrocannabinolic acid is a potent PPAR-gamma agonist with neuroprotective activity. British Journal of Pharmacology. 2017. PubMed abstract read 2026-10-22.
- Citti et al. Analysis of cannabinoids in commercial hemp seed oil and decarboxylation kinetics studies of cannabidiolic acid (CBDA). Journal of Pharmaceutical and Biomedical Analysis. 2018. PubMed abstract read 2026-10-22.
- Domenech et al. X-ray crystal structures of the cannabinoid synthases CBCAS, CBDAS and THCAS. Current Research in Structural Biology. 2026. PubMed abstract read 2026-10-22.
- Rock et al. Therapeutic Potential of Cannabidiol, Cannabidiolic Acid, and Cannabidiolic Acid Methyl Ester as Treatments for Nausea and Vomiting. Cannabis and Cannabinoid Research. 2021. PubMed abstract read 2026-10-22.
- Vigli et al. Chronic Treatment with Cannabidiolic Acid (CBDA) Reduces Thermal Pain Sensitivity in Male Mice and Rescues the Hyperalgesia in a Mouse Model of Rett Syndrome. Neuroscience. 2021. PubMed abstract read 2026-10-22.
- Binova et al. Unlocking the resorption potential of cannabidiolic acid: A comprehensive in vitro and in vivo bioavailability study. International Journal of Pharmaceutics. 2025. PubMed abstract read 2026-10-22.
- Lacerda et al. Pharmacokinetics of Non-Psychotropic Phytocannabinoids. Pharmaceutics. 2025. PubMed abstract read 2026-10-22.
- Congressional Research Service. Changes to the Statutory Definition of Hemp and Implications for Agricultural Policy (CRS In Focus IF13136), updated September 28, 2026. Read 2026-10-22.